Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 1
1998 2
1999 6
2000 9
2001 5
2002 11
2003 8
2004 17
2005 4
2006 4
2007 9
2008 9
2009 4
2010 7
2011 9
2012 9
2013 10
2014 8
2015 17
2016 13
2017 6
2018 10
2019 7
2020 12
2021 18
2022 11
2023 4
2024 4
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

214 results

Results by year

Filters applied: . Clear all
Page 1
NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry.
Alessio E, Messori L. Alessio E, et al. Molecules. 2019 May 24;24(10):1995. doi: 10.3390/molecules24101995. Molecules. 2019. PMID: 31137659 Free PMC article. Review.
NAMI-A ((ImH)[trans-RuCl(4)(dmso-S)(Im)], Im = imidazole) and KP1019/1339 (KP1019 = (IndH)[trans-RuCl(4)(Ind)(2)], Ind = indazole; KP1339 = Na[trans-RuCl(4)(Ind)(2)]) are two structurally related ruthenium(III) coordination compounds that have attracted a lot of att …
NAMI-A ((ImH)[trans-RuCl(4)(dmso-S)(Im)], Im = imidazole) and KP1019/1339 (KP1019 = (IndH)[trans-RuCl(4)(Ind)(2)], Ind = indaz …
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, Allanore Y, Matucci-Cerinic M, Distler O, Shima Y, van Laar JM, Spotswood H, Wagner B, Siegel J, Jahreis A, Denton CP; focuSSced investigators. Khanna D, et al. Lancet Respir Med. 2020 Oct;8(10):963-974. doi: 10.1016/S2213-2600(20)30318-0. Epub 2020 Aug 28. Lancet Respir Med. 2020. PMID: 32866440 Clinical Trial.
The NAMI A - human ferritin system: a biophysical characterization.
Ciambellotti S , Pratesi A , Severi M , Ferraro G , Alessio E , Merlino A , Messori L . Ciambellotti S , et al. Dalton Trans. 2018 Aug 21;47(33):11429-11437. doi: 10.1039/c8dt00860d. Dalton Trans. 2018. PMID: 30063237 Free article.
The reaction of the antimetastatic ruthenium(iii) drug NAMI A with human H-chain ferritin (HuHf) was investigated through a variety of biophysical methods. We observed that the addition of HuHf to NAMI A solutions significantly increases the rate of sp …
The reaction of the antimetastatic ruthenium(iii) drug NAMI A with human H-chain ferritin (HuHf) was investigated through a va …
Evaluation of NAMI-A Cytotoxic Effects toward Leukemia Cell Lines: A Slippery Ground Giving Misleading Messages.
Bergamo A, Sava G. Bergamo A, et al. Crit Rev Oncog. 2021;26(2):73-78. doi: 10.1615/CritRevOncog.2020036010. Crit Rev Oncog. 2021. PMID: 34347974
Among the many compounds studied, the ruthenium-based complex NAMI-A embodies the unique paradigm of the ability to selectively inhibiting and preventing the development and the growth of distant metastases originating from solid tumors in all the tumor models on wh …
Among the many compounds studied, the ruthenium-based complex NAMI-A embodies the unique paradigm of the ability to selectivel …
The Deceptively Similar Ruthenium(III) Drug Candidates KP1019 and NAMI-A Have Different Actions. What Did We Learn in the Past 30 Years?
Alessio E, Messori L. Alessio E, et al. Met Ions Life Sci. 2018 Feb 5;18:/books/9783110470734/9783110470734-007/9783110470734-011.xml. doi: 10.1515/9783110470734-011. Met Ions Life Sci. 2018. PMID: 29394024 Free article. Review.
The general interest in anticancer metal-based drugs and some encouraging pharmacological results obtained at the beginning of the investigations on innovative Ru-based drugs triggered a lot of attention on NAMI-A and KP1019, the two Ru(III) coordination compounds t …
The general interest in anticancer metal-based drugs and some encouraging pharmacological results obtained at the beginning of the investiga …
NAMI-A preferentially reacts with the Sp1 protein: understanding the anti-metastasis effect of the drug.
Yuan S , Chen S , Wu H , Jiang H , Zheng S , Zhang Q , Liu Y . Yuan S , et al. Chem Commun (Camb). 2020 Jan 30;56(9):1397-1400. doi: 10.1039/c9cc08775c. Chem Commun (Camb). 2020. PMID: 31912815
NAMI-A is highly reactive to Sp1, a tumor metastasis related protein, resulting in the perturbation of the protein structure and disruption of the DNA recognition of Sp1. Interestingly, Sp1 is more susceptible than other zinc finger proteins to NAMI-A, …
NAMI-A is highly reactive to Sp1, a tumor metastasis related protein, resulting in the perturbation of the protein structure a …
Localization of Cancer Cells for Subsequent Robust Photodynamic Therapy by ROS Responsive Polymeric Nanoparticles With Anti-Metastasis Complexes NAMI-A.
Zhang H, Cui M, Tang D, Wang B, Liang G, Xu C, Xiao H. Zhang H, et al. Adv Mater. 2024 Apr;36(14):e2310298. doi: 10.1002/adma.202310298. Epub 2024 Jan 2. Adv Mater. 2024. PMID: 38145801
Herein, a near-infrared light-activated photosensitive polymer is synthesized and branched the anti-metastatic ruthenium complex NAMI-A on the side, which is further assembled to form nanoparticles (NP2) for breast cancer therapy. ...
Herein, a near-infrared light-activated photosensitive polymer is synthesized and branched the anti-metastatic ruthenium complex NAMI …
α-Synuclein as a Target for Metallo-Anti-Neurodegenerative Agents.
Cao K, Zhu Y, Hou Z, Liu M, Yang Y, Hu H, Dai Y, Wang Y, Yuan S, Huang G, Mei J, Sadler PJ, Liu Y. Cao K, et al. Angew Chem Int Ed Engl. 2023 Jan 2;62(1):e202215360. doi: 10.1002/anie.202215360. Epub 2022 Nov 30. Angew Chem Int Ed Engl. 2023. PMID: 36345707
NAMI-A abolishes the cytotoxicity of alpha-syn towards neuronal cells and mitigates neurodegeneration and motor impairments in a rat model of Parkinson's. Multinuclear NMR and MS analyses show that NAMI-A binds to residues involved in protein aggregati …
NAMI-A abolishes the cytotoxicity of alpha-syn towards neuronal cells and mitigates neurodegeneration and motor impairments in …
A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.
Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, Lysenko L, Navarra SV, Huizinga RB; AURA-LV Study Group. Rovin BH, et al. Kidney Int. 2019 Jan;95(1):219-231. doi: 10.1016/j.kint.2018.08.025. Epub 2018 Nov 9. Kidney Int. 2019. PMID: 30420324 Free article. Clinical Trial.
NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels.
Pillozzi S, Gasparoli L, Stefanini M, Ristori M, D'Amico M, Alessio E, Scaletti F, Becchetti A, Arcangeli A, Messori L. Pillozzi S, et al. Dalton Trans. 2014 Aug 28;43(32):12150-5. doi: 10.1039/c4dt01356e. Dalton Trans. 2014. PMID: 24975719
We report here that the established anticancer ruthenium(iii) complex NAMI-A induces potent and selective cytotoxic effects in a few leukaemia cell lines. These results sound very surprising after 20 years of intense studies on NAMI-A, commonly conside …
We report here that the established anticancer ruthenium(iii) complex NAMI-A induces potent and selective cytotoxic effects in …
214 results